Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

Core Viewpoint - Celularity Inc. has resolved its compliance issues with Nasdaq, allowing its stock to continue trading on the Nasdaq Stock Market after curing its filing delinquency [1][2][3] Group 1: Compliance Resolution - The Nasdaq Listing Qualifications Hearings Panel cancelled the scheduled hearing regarding Celularity's non-compliance with Nasdaq Listing Rule 5250(c)(1) after the company filed its overdue quarterly reports [1][2] - Celularity filed its Form 10-Q for the period ended March 31, 2024, on October 16, 2024, and its Form 10-Q for the period ended June 30, 2024, on November 7, 2024, achieving compliance with Nasdaq requirements [2] Group 2: Company Statements and Challenges - Robert J. Hariri, CEO of Celularity, expressed satisfaction in meeting Nasdaq's requirements and emphasized the company's commitment to transparency and regulatory compliance [3] - The delays in filing were attributed to significant financial challenges in the biotechnology sector, which limited access to capital and affected the company's ability to secure essential audit and financial advisory services [3] Group 3: Company Overview - Celularity Inc. is focused on developing and commercializing advanced biomaterial products and placental-derived cell therapies targeting aging-related diseases, cancer, and immune disorders [4] - The company aims to leverage the unique biology of the placenta to create effective, accessible, and affordable therapeutic solutions for significant unmet global needs [4]